PROSPECTS FOR GENE-THERAPY OF HEMOPHILIA-A AND HEMOPHILIA-B

被引:14
作者
BROWNLEE, GG
机构
[1] Chemical Pathology Unit, Sir William Dunn School of Pathology, University of Oxford, Oxford
基金
英国惠康基金;
关键词
D O I
10.1093/oxfordjournals.bmb.a072956
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Haemophilia A and B are relatively rare, X-linked inherited bleeding disorders which are life-threatening to patients unless treated by regular injections of factors VIII or IX, respectively. Gene therapy offers the prospect of a cure for the disease, thus potentially freeing patients from the existing regimens of regular intravenous injection of proteins and the risks of infection by contaminating viruses. Although, in theory, gene therapy is very attractive to patients and clinicians, in practice, preclinical experiments in animal models suggests that it may be difficult to obtain adequate therapeutic levers of either factors VIII or IX for long periods of time in patients unless improved methods can be devised. Progress in the preclinical studies is more encouraging with haemophilia B than with haemophilia A. Clinical trials for haemophilia B patients have started in China.
引用
收藏
页码:91 / 105
页数:15
相关论文
共 37 条
[1]  
ANSON DS, 1987, MOL BIOL MED, V4, P11
[2]   EXPRESSION OF HUMAN FACTOR-IX IN RABBIT HEPATOCYTES BY RETROVIRUS-MEDIATED GENE-TRANSFER - POTENTIAL FOR GENE-THERAPY OF HEMOPHILIA-B [J].
ARMENTANO, D ;
THOMPSON, AR ;
DARLINGTON, G ;
WOO, SLC .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1990, 87 (16) :6141-6145
[3]   PHENOTYPIC CORRECTION OF FACTOR-IX DEFICIENCY IN SKIN FIBROBLASTS OF HEMOPHILIC DOGS [J].
AXELROD, JH ;
READ, MS ;
BRINKHOUS, KM ;
VERMA, IM .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1990, 87 (13) :5173-5177
[4]   DEFECTIVE PROPEPTIDE PROCESSING OF BLOOD-CLOTTING FACTOR-IX CAUSED BY MUTATION OF ARGININE TO GLUTAMINE AT POSITION -4 [J].
BENTLEY, AK ;
REES, DJG ;
RIZZA, C ;
BROWNLEE, GG .
CELL, 1986, 45 (03) :343-348
[5]  
BRETTLER DB, 1989, BLOOD, V73, P2067
[6]  
BROWNLEE GG, 1987, BIOCHEM SOC T, V15, P1
[7]   GENE-THERAPY VIA PRIMARY MYOBLASTS - LONG-TERM EXPRESSION OF FACTOR-IX PROTEIN FOLLOWING TRANSPLANTATION INVIVO [J].
DAI, Y ;
ROMAN, M ;
NAVIAUX, RK ;
VERMA, IM .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1992, 89 (22) :10892-10895
[8]   FACTOR-XI ACTIVATION IN A REVISED MODEL OF BLOOD-COAGULATION [J].
GAILANI, D ;
BROZE, GJ .
SCIENCE, 1991, 253 (5022) :909-912
[9]   TOWARDS GENE-THERAPY FOR HEMOPHILIA-B USING PRIMARY HUMAN KERATINOCYTES [J].
GERRARD, AJ ;
HUDSON, DL ;
BROWNLEE, GG ;
WATT, FM .
NATURE GENETICS, 1993, 3 (02) :180-183
[10]   SUBCUTANEOUS INJECTION OF FACTOR-IX FOR THE TREATMENT OF HEMOPHILIA-B [J].
GERRARD, AJ ;
AUSTEN, DEG ;
BROWNLEE, GG .
BRITISH JOURNAL OF HAEMATOLOGY, 1992, 81 (04) :610-613